ReviewCellular and molecular neurobiology2022
Dysbiosis and Alzheimer's Disease: Cause or Treatment Opportunity?
Review in Cellular and molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- The causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic review.The Journal of physiology · 2026Pooled it
- Plant Polysaccharides in Alzheimer's Disease: From Phytochemistry to Microbiota-Gut-Brain Axis Mechanisms-Resolving the Pharmacokinetic-Pharmacodynamic Paradox.Molecules (Basel, Switzerland) · 2026Review
- From the hive to the brain: synergistic potential of honeybee products with alzheimer's drugs.Metabolic brain disease · 2025Review
- Impact of Gut-Brain Axis and Probiotics on Alzheimer's Disease.Neurology international · 2025Review
- The MR1/MAIT cell axis impacts the gut-brain axis through both cognition and microbial community structure in 5XFAD mice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Capsaicin as a Microbiome Modulator: Metabolic Interactions and Implications for Host Health.Metabolites · 2025Review
- Gastrointestinal exposure to silica nanoparticles induced Alzheimer's disease-like neurotoxicity in mice relying on gut microbiota and modulation through TLR4/NF-κB and HDAC.Journal of nanobiotechnology · 2025Article
- Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer's Disease: Beneficial or Detrimental?Antioxidants (Basel, Switzerland) · 2024Review
- Brain-Gut and Microbiota-Gut-Brain Communication in Type-2 Diabetes Linked Alzheimer's Disease.Nutrients · 2024Review
- The link between gut microbiome and Alzheimer's disease: From the perspective of new revised criteria for diagnosis and staging of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer's disease.Cell reports · 2024Article
- Herbal medicines in Alzheimer's disease and the involvement of gut microbiota.Frontiers in pharmacology · 2024Review
- Active Compounds ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice.Biomedicines · 2023Review
- Gut Microbiota is an Impact Factor based on the Brain-Gut Axis to Alzheimer's Disease: A Systematic Review.Aging and disease · 2023Review
- The Association between Dysbiosis and Neurological Conditions Often Manifesting with Chronic Pain.Biomedicines · 2023Review
- Gut Microbiota and Alzheimer's Disease: How to Study and Apply Their Relationship.International journal of molecular sciences · 2023Review
- Advances in the study of the effects of gut microflora on microglia in Alzheimer's disease.Frontiers in molecular neuroscience · 2023Review
- The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease.IBRO neuroscience reports · 2022Review
- Gut-Brain Axis, Neurodegeneration and Mental Health: A Personalized Medicine Perspective.Indian journal of microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent investigations have increased the interest on the connection between the microorganisms inhabiting the gut (gut microbiota) and human health. An imbalance of the intestinal bacteria representation (dysbiosis) could lead to different diseases, ranging from obesity and diabetes, to neurological disorders including Alzheimer's disease (AD). The term "gut-brain axis" refers to a crosstalk between the brain and the gut involving multiple overlapping pathways, including the autonomic, neuroendocrine, and immune systems as well as bacterial metabolites and neuromodulatory molecules. Through this pathway, microbiota can influence the onset and progression of neuropathologies such as AD. This review discusses the possible interaction between the gut microbiome and AD, focusing on the role of gut microbiota in neuroinflammation, cerebrovascular degeneration and Aβ clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.